PAP Therapy in Patients With Obesity Hypoventilation Syndrome
PAP Therapy in Patients With Obesity Hypoventilation Syndrome
The role of different levels of compliance and long-term effects of positive airway pressure
 (PAP) therapy on gas exchange, sleepiness, quality of life, depression and death rate in
 patients with obesity hypoventilation syndrome (OHS).
Various forms of positive airway pressure (PAP) therapy are effective in providing short and
 long-term benefits in these patients with or without obstructive sleep apnea (OSA). However,
 there are limited data concerning the impact of long-term effects of PAP therapy on survival
 and functional status in individuals with obesity hypoventilation syndrome (OHS) and OSA.
 Therefore we aimed to assess the role of different levels of compliance and long-term effects
 of PAP on gas exchange, sleepiness, quality of life, depression and death rate in patients
 with OHS, two year after PAP initiation.
Inclusion Criteria:

 -  aged between 18 and 80 years

 -  Obesity hypoventilation syndrome diagnosis (OHS)

 -  clinically stable for at least 4 weeks prior to the enrolmenT

 -  above-elementary school education.

 Exclusion Criteria:

 -  refusal to participate

 -  refusal of PAP therapy

 -  central sleep apnea syndromes

 -  restrictive ventilation syndromes

 -  severe congestive heart failure

 -  a history of life-threatening arrhythmias

 -  severe cardiomyopathy

 -  significant chronic kidney disease

 -  untreated hypothyroidism

 -  family or personal history of mental illness

 -  drug or alcohol abuse

 -  sedative use

 -  severe cognitive impairment

 -  concurrent oncological diseases

 -  history of narcolepsy or restless legs syndrome.